Navigation Links
Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 25th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 3rd  at 11:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company plans to resubmit the Contrave NDA to the FDA with potential approval by June 2014.The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Announces Successful Interim Analysis of Contrave Light Study
2. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
5. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
6. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... den Markt gebracht, die es Ärzten erlaubt, ihre ... zu behandeln: MDLinking kombiniert Live Streaming mit einer ... Umfeld zu kommunizieren. Mediziner in Europa, Afrika, Asien ... sich bereits für die Plattform registriert. ...
(Date:5/24/2016)... CHRISTCHURCH, New Zealand , May 24, 2016 ... scanning and informatics solutions for the healthcare sector, has been ... the New Zealand Hi-Tech Awards 2016. Dr ... a fantastic acknowledgement for our team.  It,s really good to ... the burden healthcare internationally. Our products are used in 35 ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... corporate identity and website at its “Transforming Outcomes” User Conference in Las Vegas ... reflect i2i’s ongoing success to set the market standard for meaningful population health ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... of communication enabled solutions and managed services today announced a strategic partnership ... enterprise contact center market. , Altura, one of Avaya’s largest Platinum Business ...
(Date:5/24/2016)... Church, VA (PRWEB) , ... May 24, 2016 , ... ... 14-15, 2016 · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to ... is unlikely that human error will ever be totally eliminated, many human performance problems ...
(Date:5/24/2016)... ... ... Regenerative Medicine is being transformed by ongoing research and clinical findings at ... results as have been achieved with Okyanos Cell Therapy are paving the ... patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric Duckers, MD, PhD, ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... or injury that focuses on repairing the musculoskeletal and neuromuscular systems of the ... on functional restoration, NYDNRehab began providing treatments for physical therapy in New York, ...
Breaking Medicine News(10 mins):